Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix Journal Article


Authors: Tang, L. H.; Shia, J.; Soslow, R. A.; Dhall, D.; Wong, W. D.; O'reilly, E.; Qin, J.; Paty, P.; Weiser, M. R.; Guillem, J.; Temple, L.; Sobin, L. H.; Klimstra, D. S.
Article Title: Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix
Abstract: Appendiceal tumors exhibiting both neuroendocrine and glandular differentiation are uncommon and have caused difficulty in pathologic classification, prediction of prognosis, and clinical management. Previously, such lesions have been variously designated as adenocarcinoid, goblet cell carcinoid (GCC), and mixed adenocarcinoma carcinoid. In this study, we undertook a retrospective investigation of 63 such cases and classified them as typical GCC (group A) and adenocarcinoma ex GCC on the basis of the histologic features of the tumor at the primary site. The adenocarcinoma ex GCC group was further divided into signet ring cell type (group B) and poorly differentiated adenocarcinoma type (group C). The clinical characteristics and prognosis were compared within these groups and with conventional de novo appendiceal adenocarcinomas. Both groups A and B tumors shared a similar immunoprofile, which included generally focal immunoreactivity for neuroendocrine markers, and a normal intestinal type mucin glycoprotein profile (negative MUC1 expression and preserved MUC2 immunoreactivity). The proliferative index was relatively low in these tumors and slightly increased from groups A to B tumors (11% to 16%). Both β-catenin and E-cadherin exhibited a normal membranous staining pattern in groups A and B tumors. The poorly differentiated adenocarcinomas ex GCC (group C) demonstrated abnormal p53 and β-catenin immunoreactivity. The mean follow-up time was 49±5 (SE) months. The overall disease-specific survival for all subtypes was 77%, with 46% of patients without evidence of disease and 31% alive with disease. The mean survival was 43±7 months. All the patients with clinical stage of I or IIA disease had a favorable outcome after appropriate surgery with or without chemotherapy. Although most patients (63%) with GCC presented at an advanced clinical stage, their clinical outcome could be differentiated by subclassification of tumors. The stage IV-matched 5-year survival was 100%, 38%, and 0% for groups A, B, and C, respectively. In conclusion, GCC is a distinctive appendiceal neoplasm that exhibits unique pathologic features and clinical behavior. They display a spectrum of histologic features and possess the potential to transform to an adenocarcinoma phenotype of either signet ring cell or poorly differentiated adenocarcinoma types. Careful evaluation of the morphologic features of GCCs and appropriate pathologic classification are crucial for clinical management and prediction of outcome. Surgical management with right hemicolectomy is recommended after appendectomy for most cases, particularly those with an adenocarcinoma component (groups B and C). © 2008 Lippincott Williams & Wilkins.
Keywords: cancer chemotherapy; cancer survival; controlled study; protein expression; treatment outcome; disease-free survival; middle aged; cancer surgery; retrospective studies; major clinical study; antineoplastic agents; comparative study; disease free survival; chemotherapy, adjuvant; cancer staging; antineoplastic agent; neoplasm staging; adenocarcinoma; cell proliferation; tumor localization; classification; observer variation; tumor differentiation; cell differentiation; pathology; immunoreactivity; retrospective study; protein p53; uvomorulin; time; time factors; kaplan-meiers estimate; immunology; adjuvant chemotherapy; appendix; colon resection; terminology as topic; carcinoid; nomenclature; mucin 1; kaplan meier method; appendectomy; beta catenin; carcinoid tumor; signet ring carcinoma; carcinoma, signet ring cell; goblet cell; appendix tumor; colectomy; appendiceal neoplasms; mucin 2; goblet cell carcinoid; krukenberg tumor; signet ring cell carcinoma
Journal Title: American Journal of Surgical Pathology
Volume: 32
Issue: 10
ISSN: 0147-5185
Publisher: Lippincott Williams & Wilkins  
Date Published: 2008-10-01
Start Page: 1429
End Page: 1443
Language: English
DOI: 10.1097/PAS.0b013e31817f1816
PUBMED: 18685490
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 32" - "Export Date: 17 November 2011" - "CODEN: AJSPD" - "Source: Scopus"
Altmetric
Citation Impact
MSK Authors
  1. Deepti Dhall
    23 Dhall
  2. Philip B Paty
    469 Paty
  3. Jose Guillem
    414 Guillem
  4. David S Klimstra
    976 Klimstra
  5. Jinru Shia
    669 Shia
  6. Martin R Weiser
    492 Weiser
  7. Robert Soslow
    790 Soslow
  8. Laura Hong Tang
    426 Tang
  9. Eileen O'Reilly
    688 O'Reilly
  10. Larissa Temple
    192 Temple
  11. Douglas W Wong
    178 Wong